Skorupski Wojciech J, Pietrasik Arkadiusz, Gąsecka Aleksandra, Sacha Jerzy, Pawłowski Tomasz, Bielawski Gabriel, Balak Wojciech, Sukiennik Adam, Burzyńska Paulina, Witkowski Adam, Warniełło Mateusz, Rzeszutko Łukasz, Bartuś Stanisław, Pawlik Artur, Kaczyński Mateusz, Gil Robert, Kuliczkowski Wiktor, Reczuch Krzysztof, Protasiewicz Marcin, Legutko Jacek, Kleczyński Paweł, Wańczura Piotr, Gurba Sebastian, Kochanowska Anna, Łomiak Michał, Krajsman Maciej, Skorupski Włodzimierz, Zarębiński Maciej, Pawluczuk Piotr, Włodarczak Szymon, Włodarczak Adrian, Ściborski Krzysztof, Telichowski Artur, Pluciński Mieszko, Hiczkiewicz Jarosław, Konsek Karolina, Hawranek Michał, Gąsior Mariusz, Peruga Jan, Fiutowski Marcin, Romanek Robert, Kasprzyk Piotr, Ciećwierz Dariusz, Ochała Andrzej, Wojakowski Wojciech, Kochman Janusz, Lesiak Maciej, Grygier Marek
1st Department of Cardiology, Poznan University of Medical Sciences, Poland.
Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Cardiol J. 2025;32(3):248-257. doi: 10.5603/cj.103336. Epub 2025 Apr 14.
The Impella percutaneous mechanical circulatory support device provides improved support in treating patients with high-risk percutaneous coronary interventions (HR-PCI) or in cardiogenic shock. IMPELLA-PL is a multicenter registry developed to share clinical data and experiences using Impella technology in Poland. The retrospective analysis conducted in this study aims to fill the knowledge gap of Impella performance in patients with multivessel coronary artery disease (CAD) and depressed left ventricular ejection fraction (EF) (≤30%) treated with HR-PCI.
Retrospective data were analyzed from patients presenting with multivessel coronary disease and low EF treated with Impella CP collected from 20 Polish interventional cardiology centers registered with IMPELLA-PL to assess the safety and efficacy in short- and long-term clinical outcomes.
A total of 115 patients with low EF received Impella CP support during HR-PCI. The success rate of Impella supported HR-PCI was high (99.1%) with an average hospital stay of 15.6 ± 10.7 days. The right femoral artery was the most common access (55.7%) followed by the left femoral artery (37.4%). The in-hospital mortality rate was 6.1%, and the all-cause mortality rate at one year was 13.9%.
High-risk PCI with Impella CP periprocedural support was safe and effective in patients with low EF (≤30%). The all-cause mortality rate (6.1% and 13.9%, respectively, for in-hospital and at 12-months) was comparable with other Impella registries.
Impella经皮机械循环支持装置在治疗高危经皮冠状动脉介入治疗（HR-PCI）患者或心源性休克患者时能提供更好的支持。IMPELLA-PL是一个多中心注册研究，旨在分享在波兰使用Impella技术的临床数据和经验。本研究进行的回顾性分析旨在填补HR-PCI治疗的多支冠状动脉疾病（CAD）和左心室射血分数降低（EF）（≤30%）患者中Impella性能的知识空白。
对来自20个注册于IMPELLA-PL的波兰介入心脏病学中心的接受Impella CP治疗的多支冠状动脉疾病和低EF患者的回顾性数据进行分析，以评估短期和长期临床结局的安全性和有效性。
共有115例低EF患者在HR-PCI期间接受了Impella CP支持。Impella支持的HR-PCI成功率很高（99.1%），平均住院时间为15.6±10.7天。右股动脉是最常用的入路（55.7%），其次是左股动脉（37.4%）。住院死亡率为6.1%，一年全因死亡率为13.9%。
对于低EF（≤30%）患者，Impella CP围手术期支持的高危PCI是安全有效的。全因死亡率（住院时和12个月时分别为6.1%和13.9%）与其他Impella注册研究相当。
